Large and consistent evidence supports the role of body mass index (BMI) as a prognostic and predictive indicator in breast cancer. However, there is paucity of data specifically referred to women diagnosed at a young age across the different disease settings. We investigated the impact of BMI on treatment outcomes in 86 breast cancer patients aged 45 y or less treated with neoadjuvant chemotherapy (CT) followed by surgery
Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger. Evidence from a historic cohort / D'Aiuto, Massimiliano; Chirico, Andrea; De Riggi, Michele Antonio; Frasci, Giuseppe; De Laurentiis, Michelino; Di Bonito, Maurizio; Vici, Patrizia; Pizzuti, Laura; Sergi, Domenico; Maugeri Saccà, Marcello; Barba, Maddalena; Giordano, Antonio. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - 17:5(2016), pp. 470-476. [10.1080/15384047.2016.1156265]
Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger. Evidence from a historic cohort
CHIRICO, ANDREA;
2016
Abstract
Large and consistent evidence supports the role of body mass index (BMI) as a prognostic and predictive indicator in breast cancer. However, there is paucity of data specifically referred to women diagnosed at a young age across the different disease settings. We investigated the impact of BMI on treatment outcomes in 86 breast cancer patients aged 45 y or less treated with neoadjuvant chemotherapy (CT) followed by surgery| File | Dimensione | Formato | |
|---|---|---|---|
|
D'Aiuto_Body-mass_2016.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
735.62 kB
Formato
Adobe PDF
|
735.62 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
